Bridging to CD19 CAR T-cell therapy for large B-cell lymphoma: An analysis of 1,134 patients by the EBMT Lymphoma Working Party and the GoCART Coalition
Year: 2026
Type: article
Study design: Observational Study
Abstract: CD19-directed CAR T-cell therapy (CAR T) is effective in relapsed/refractory large B-cell lymphoma (R/R LBCL), but the role of bridging therapy (BT) remains incompletely defined. We analyzed 1,134 patients with R/R LBCL treated with axicabtagene ciloleucel or tisagenlecleucel between 2018 and July 2023. BT was categorized as polatuzumab vedotin-bendamustine-rituximab (Pola-BR), low-dose regimens, classical salvage chemo-immunotherapy, or radiotherapy. Overall survival (OS) and progression-free survival (PFS) from CAR T infusion were primary endpoints. Overall, 900 patients (79.5%) received BT and 232 (20.5%) did not (No-BT). At lymphodepletion, BT recipients more often had elevated LDH, bulky disease, and ECOG ≥2, yet had higher complete remission rates. Three-year PFS was 34.3% with BT versus 44.7% with No-BT, and OS was 44.4% versus 57.4%. In multivariable analyses, No-BT remained associated with superior OS (HR 0.63, 95% CI 0.49-0.82) and PFS (HR 0.69, 95% CI 0.55-0.87). Improvement in disease status between apheresis and lymphodepletion occurred more often with BT and was associated with improved outcomes (3-year PFS 47.5% vs. 28.9 and 27.7% for stable/worsened disease among BT recipients). BT modality influenced conversion rates but not adjusted OS, PFS, or relapse. Our data suggest bridging therapy may prioritize disease control with minimal toxicity rather than any specific regimen.
Source: Bone Marrow Transplantation
Authors: Philipp Berning, Christophe Peczynski, Jan C. Schroeder, Eva Michel, Michael Oertel, Fizza Imran, Evgenii Shumilov, Imke E. Karsten, Robin Sanderson, Urban Novak, Ron Ram, Peter Dreger, David Beauvais, Maxime Delforge, Daniela Taurino, Robin Noel, Almudena Cabero, Ralph Wäsch, Malte von Bonin, Peter Vandenberghe, Olaf Penack, Björn Chapuy, Avichai Shimoni, Barbara Dreta, Ulf Schnetzke, Eugenio Galli, Anna Ossami Saidy, Georg Lenz, Bertram Glass, Anna Sureda, Ali Bazarbachi, Wolfgang Bethge, Norbert Schmitz, on behalf of the GoCART Coalition
Institutions: University Hospital Münster, European Society for Blood and Marrow Transplantation, European Society for Blood and Marrow Transplantation, University of Tübingen, King's College Hospital, University of Bern, University Hospital of Bern, Tel Aviv University, Tel Aviv Sourasky Medical Center, Heidelberg University, Centre Hospitalier Universitaire de Lille, IRCCS Humanitas Research Hospital, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Biología Molecular y Celular del Cáncer de Salamanca, University of Freiburg, Universitair Ziekenhuis Leuven, Charité – Universitätsmedizin Berlin, Sheba Medical Center, University Hospital Centre Zagreb, Jena University Hospital, Agostino Gemelli University Polyclinic, Helios Hospital Berlin-Buch, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Universitat de Barcelona, American University of Beirut Medical Center, American University of Beirut
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,990
OpenAlex ID: W7226007310
